Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iTHER Sub-Protocol D: trametinib with dexamethasone, cyclophosphamide, and cytarabine in relapsed or refractory pediatric hematologic malignancies
NL-OMON53652Phase 2Not yet recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trametinib, dexamethasone, cyclophosphamide and cytarabine in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), t-cell acute lymphoblastic leukemia (T-ALL) and 2 more (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Maximum tolerated dose, Recommended phase II dose and 1 more. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
trametinibdexamethasonecyclophosphamidecytarabine
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)t-cell acute lymphoblastic leukemia (T-ALL)T-lymphoblastic lymphoma (T-LBL)B lymphoblastic lymphoma (B-LL)
Beyond the preview
Go deeper on NL-OMON53652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53652.